Prepared in accordance with the provisions of KKDIK Annex-2 Regulation, 23.06.2017, No: 30105



Moxifloxacin Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 2437922-00014
 Date of first issue: 09.02.2018

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Moxifloxacin Solid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-

stance/Mixture

: Pharmaceutical

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

Kilsheelan

. Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person

responsible for the SDS

EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

National Poison Control Center (UZEM): 114

Emergency: 1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification T.R. SEA No 28848 and subsequent amendments

Acute toxicity, Category 4 H302: Harmful if swallowed.

Eye irritation, Category 2 H319: Causes serious eye irritation.

Reproductive toxicity, Category 2 H361d: Suspected of damaging the unborn child. Specific target organ toxicity - repeated H373: May cause damage to organs through pro-

exposure, Category 2 longed or repeated exposure.

2.2 Label elements

Labelling T.R. SEA No 28848 and subsequent amendments

Hazard pictograms

(!)

Signal word : Warning

Prepared in accordance with the provisions of KKDIK Annex-2 Regulation, 23.06.2017, No: 30105



Moxifloxacin Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 2437922-00014
 Date of first issue: 09.02.2018

Hazard statements : H302 Harmful if swallowed.

H319 Causes serious eye irritation.

H361d Suspected of damaging the unborn child.

H373 May cause damage to organs through prolonged or

repeated exposure.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON

CENTER/ doctor if you feel unwell. Rinse mouth.

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

P337 + P313 If eye irritation persists: Get medical advice/

attention.

Hazardous components which must be listed on the label:

Moxifloxacin HCL

2.3 Other hazards

None known.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. KKDIK Registra- tion No.	SEA Classification	Concentration (% w/w)			
Moxifloxacin HCL	186826-86-8	Acute Tox. 4; H302 Eye Irrit. 2; H319 Repr. 2; H361d STOT RE 2; H373 (Liver)	>= 40 - <= 70			
Substances with a workplace exposure limit :						
Cellulose	9004-34-6 232-674-9		>= 10 - <= 30			

For explanation of abbreviations see section 16.

Prepared in accordance with the provisions of KKDIK Annex-2 Regulation, 23.06.2017, No: 30105



Moxifloxacin Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 2437922-00014
 Date of first issue: 09.02.2018

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed

Risks : Harmful if swallowed.

Causes serious eye irritation.

Suspected of damaging the unborn child.

May cause damage to organs through prolonged or repeated

exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Prepared in accordance with the provisions of KKDIK Annex-2 Regulation, 23.06.2017, No: 30105



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 2437922-00014 Date of first issue: 09.02.2018

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- : Carbon oxides

5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Use personal protective equipment. Personal precautions

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions Avoid release to the environment.

> Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

Prepared in accordance with the provisions of KKDIK Annex-2 Regulation, 23.06.2017, No: 30105



Moxifloxacin Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 2437922-00014
 Date of first issue: 09.02.2018

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust, fume, gas, mist, vapours or spray.

Do not swallow. Do not get in eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store locked up. Store in

accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis	
Moxifloxacin HCL	186826-86- 8	TWA	1000 μg/m3 (OEB 1)	Internal	
Cellulose	9004-34-6	ZOAD/TWA (To- tal dust)	15 mg/m3	TR OEL DU	
	Further information: Allowable occupational exposure limit values of chemicals in dust form				

Prepared in accordance with the provisions of KKDIK Annex-2 Regulation, 23.06.2017, No: 30105



Moxifloxacin Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 2437922-00014
 Date of first issue: 09.02.2018

		ZOAD/TWA (Respirable dust)	5 mg/m3	TR OEL DU			
	Further information: Allowable occupational exposure limit values of che in dust form						

8.2 Exposure controls

Engineering measures

Use feasible engineering controls to minimize exposure to compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Skin and body protection : Work uniform or laboratory coat.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Equipment should conform to TS EN 143

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance : solid
Colour : pink
Odour : odourless

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : Not classified as a flammability hazard

Upper explosion limit / Upper

flammability limit

No data available

Prepared in accordance with the provisions of KKDIK Annex-2 Regulation, 23.06.2017, No: 30105



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 2437922-00014 Date of first issue: 09.02.2018

Lower explosion limit / Lower

flammability limit

No data available

No data available Vapour pressure

Relative vapour density No data available

Relative density No data available

Density No data available

Solubility(ies)

Water solubility No data available Partition coefficient: n-

octanol/water

No data available

No data available Auto-ignition temperature

No data available Decomposition temperature

Viscosity

Viscosity, kinematic No data available

Explosive properties Not explosive

Oxidizing properties The substance or mixture is not classified as oxidizing.

9.2 Other information

Flammability (liquids) No data available

Molecular weight Not applicable

Particle size No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid None known.

10.5 Incompatible materials

Materials to avoid Oxidizing agents

Prepared in accordance with the provisions of KKDIK Annex-2 Regulation, 23.06.2017, No: 30105



Moxifloxacin Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 30.09.2023

 5.0
 06.04.2024
 2437922-00014
 Date of first issue: 09.02.2018

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of:

Ingestion

Eye contact

Skin contact

Acute toxicity

Harmful if swallowed.

Product:

exposure

Acute oral toxicity : Acute toxicity estimate: 1.886 mg/kg

Method: Calculation method

Components:

Moxifloxacin HCL:

Acute oral toxicity : LD50 (Rat): 1.320 mg/kg

LD50 (Mouse): > 435 mg/kg

LD50 (Monkey): 1.500 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5,8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Moxifloxacin HCL:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye irritation.

Prepared in accordance with the provisions of KKDIK Annex-2 Regulation, 23.06.2017, No: 30105



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 2437922-00014 Date of first issue: 09.02.2018

Components:

Moxifloxacin HCL:

Species : Rabbit

Result : Moderate eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Components:

Moxifloxacin HCL:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: positive

Test Type: Chromosome aberration test in vitro

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: in vitro micronucleus test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Application Route: Oral Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Carcinogenicity

Not classified based on available information.

Prepared in accordance with the provisions of KKDIK Annex-2 Regulation, 23.06.2017, No: 30105



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 2437922-00014 Date of first issue: 09.02.2018

Components:

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Moxifloxacin HCL:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: LOAEL: 500 mg/kg body weight

Result: Effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Monkey

Application Route: Oral

Developmental Toxicity: NOAEL: 10 mg/kg body weight

Result: negative

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Intravenous injection

Developmental Toxicity: LOAEL: 20 mg/kg body weight

Symptoms: Skeletal malformations

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Prepared in accordance with the provisions of KKDIK Annex-2 Regulation, 23.06.2017, No: 30105



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 2437922-00014 Date of first issue: 09.02.2018

Components:

Moxifloxacin HCL:

Target Organs : Liver

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Moxifloxacin HCL:

Species : Rat

LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 4 Weeks

Species : Rat

NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Liver

Symptoms : Liver disorders

Species : Rat

NOAEL : 20 mg/kg

Application Route : Oral

Exposure time : 6 Months

Target Organs : Liver

Symptoms : Liver disorders

Species: MonkeyNOAEL: 50 mg/kgApplication Route: OralExposure time: 4 Weeks

Symptoms : No adverse effects

Species : Monkey
NOAEL : 15 mg/kg
Application Route : Oral
Exposure time : 13 Weeks

Target Organs : Gastrointestinal tract

Symptoms : Vomiting

Species : Monkey
Application Route : Oral
Exposure time : 26 Weeks
Target Organs : Liver

Symptoms : Liver disorders

Cellulose:

Species : Rat

Prepared in accordance with the provisions of KKDIK Annex-2 Regulation, 23.06.2017, No: 30105



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 2437922-00014 Date of first issue: 09.02.2018

NOAEL : >= 9.000 mg/kg

Application Route : Ingestion Exposure time : 90 Days

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Moxifloxacin HCL:

Ingestion : Symptoms: Nausea, Abdominal pain, Headache, Dizziness,

central nervous system effects, joint pain

SECTION 12: Ecological information

12.1 Toxicity

Components:

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

12.2 Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

12.3 Bioaccumulative potential

No data available

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Not relevant

12.6 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

Prepared in accordance with the provisions of KKDIK Annex-2 Regulation, 23.06.2017, No: 30105



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 2437922-00014 Date of first issue: 09.02.2018

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA (Cargo) : Not regulated as a dangerous good
IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

Prepared in accordance with the provisions of KKDIK Annex-2 Regulation, 23.06.2017, No: 30105



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 2437922-00014 Date of first issue: 09.02.2018

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

KKDIK (30105 (Bis)) - Restrictions on the manufacture, : Not applicable

placing on the market and use of certain dangerous

substances, mixtures and articles (Annex 17)

Regulation on Persistent Organic Pollutants (Number : Not applicable

30595 and subsequent amendments published)

Regulation on prevention of major industrial accidents. Reg number 30702

Not applicable

Other regulations:

T.R. Regulation on Classification, Labeling and Packaging of Substances and Mixtures, dated December 11, 2013 and numbered 28848 from the Ministry of Environment and Urbanization and the subsequent amendments published.

Regulation on Dust Control (No: 28812, 2013). Occupational Dust Exposure Limit Values (Annex 1)

Regulation on Import and Export of Certain Hazardous : Not applicable

Chemicals, No. 32087, 2023

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

The SDS has been prepared by: Name: Gökhan Ardıç; Contact email: sds@chemleg.com; Telephone number: +90 216 706 1307; Certificate Number: Lonca KDU 34 / 2020.08; Certificate Date: 22 September 2020; Valid Until: 22 September

2025

Prepared in accordance with the provisions of KKDIK Annex-2 Regulation, 23.06.2017, No: 30105



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 2437922-00014 Date of first issue: 09.02.2018

Full text of H-Statements

H302 : Harmful if swallowed.

H319 : Causes serious eye irritation.

H361d : Suspected of damaging the unborn child.

H373 : May cause damage to organs through prolonged or repeated

exposure.

The Turkish SDS has been prepared according to the Regulation on Safety Data Sheets for Hazardous Substances and Mixtures No. 29204.

Full text of other abbreviations

Acute Tox. : Acute toxicity Eye Irrit. : Eye irritation

Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure

TR OEL DU : Türkiye. Regulation on Dust Control. Occupational Dust Expo-

sure Limit Values (Annex 1)

TR OEL DU / ZOAD/TWA : Time Weighted Average Value

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule: ENCS - Existing and New Chemical Substances (Japan): ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Prepared in accordance with the provisions of KKDIK Annex-2 Regulation, 23.06.2017, No: 30105



Moxifloxacin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 30.09.2023 5.0 06.04.2024 2437922-00014 Date of first issue: 09.02.2018

Sources of key data used to compile the Safety Data

eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Internal technical data, data from raw material SDSs, OECD

Sheet cy, http://echa.europa.eu

Classification of the mixture: Classification procedure:

Acute Tox. 4 H302 Calculation method
Eye Irrit. 2 H319 Calculation method
Repr. 2 H361d Calculation method
STOT RE 2 H373 Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

TR / EN